LinkedIn

ABILITA BIO

noun | abil·i·ta | \ə-ˈbi-lə-tə\

ABILITA BIO IS FOCUSED ON DEVELOPING TECHNOLOGIES TO ENABLE DISCOVERY AND DEVELOPMENT OF DRUGS TARGETING MEMBRANE PROTEINS, INCLUDING G PROTEIN-COUPLED RECEPTORS (GPCRs) AND ION CHANNELS. WE HAVE ESTABLISHED COLLABORATIONS, AND SEEK TO EXPAND COLLABORATIVE RESEARCH AGREEMENTS WITH GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES.

WHAT DO WE DO?

WE OFFER PARTNERS A TECHNICAL SOLUTION THROUGH GENERATION OF ENABLED MEMBRANE PROTEINS (EMPs™)

Antibody Discovery

Compound Screening

Crystallography

HOW ABOUT SOME FACTS ABOUT THE MARKET FOR MEMBRANE PROTEIN-TARGETING THERAPIES?

>0
Medically relevant targets
0%
Global revenue of marketed therapies
0
GPCRs currently targeted by small molecules or peptides
$0B
Annual global revenue

 

ONLY ONE THERAPEUTIC ANTIBODY IS APPROVED IN THE WORLD TARGETING GPCRs

ABILITA BIO IS JUST GETTING STARTED

THE CHALLENGE

Drug discovery targeting GPCRs and ion channels is inherently difficult due to the notoriously low stability and high conformational flexibility of these integral membrane proteins, especially when removed from the cellular environment. This intrinsic characteristic of membrane proteins has greatly limited the success of protein-based small molecule screening and structure-guided drug discovery, as well as antibody discovery efforts.

OUR SOLUTION

Abilita Bio offers partners a technical solution through the generation of Enabled Membrane Proteins (EMPs™) for use in drug discovery and development, including antibody discovery programs. Providing enhanced tool receptors for antibody discovery represents a unique market opportunity, minimally available today to the Pharmaceutical Industry.